LONDON – Russia's state-owned investment firm Rusnano has made its first foray into U.S. biotech, joining existing and other new investors in private funding rounds totaling $94.5 million for nanomedicine specialists Selecta Biosciences Inc. and Bind Biosciences Inc.Rusnano's contribution of $50 million will be divided equally between the two companies, with each raising a further $22.25 million to complete the rounds.